Lexaria Bioscience
LEXXLexaria Bioscience Corp. is a biotechnology company that enhances the bioavailability and performance of active pharmaceutical ingredients (APIs) using its patented DehydraTECH drug delivery platform.
Earnings
Next report
Oct 28, 2026 (in 2 months)Competitors
Profile
Lexaria Bioscience Corp. is a biotechnology company that enhances the bioavailability and performance of active pharmaceutical ingredients (APIs) using its patented DehydraTECH drug delivery platform. The technology improves the way molecules enter the bloodstream through oral ingestion, aiming to increase effectiveness, lower dosing requirements, and improve patient tolerability. The company primarily focuses on pharmaceutical applications for cardiometabolic diseases, while also licensing its technology for nutraceuticals and consumer products.
A specialized drug delivery innovator with a significant patent portfolio focused on oral bioavailability and palatability of lipophilic active agents.
FAQ
- What is Lexaria Bioscience's market cap?
- Lexaria Bioscience (LEXX) has a market capitalization of $18.2M and trades on NASDAQ.
- Who are Lexaria Bioscience's competitors?
- Lexaria Bioscience's key competitors include Eli Lilly and Company, vTv Therapeutics Inc. Class A Common Stock, DiaMedica Therapeutics Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Lexaria Bioscience partner with?
- Lexaria Bioscience's notable partners include Altria Client Services LLC, Hill Inc., Boldt Runners Corporation, and others.
- What subsidiaries does Lexaria Bioscience have?
- Lexaria Bioscience's subsidiaries include Poviva Corp., Lexaria Nicotine LLC, Lexaria Pharmaceutical Corp., and others.
- Where is Lexaria Bioscience headquartered?
- Lexaria Bioscience is headquartered in Canada and employs approximately 3 people. It has been publicly traded since 2006.